Vivos Therapeutics, Inc. (VVOS) Reports Q4 Loss, Lags Revenue Estimates

Company Performance - Vivos Therapeutics, Inc. reported a quarterly loss of $0.28 per share, which was better than the Zacks Consensus Estimate of a loss of $0.43, and a significant improvement from a loss of $3.05 per share a year ago, resulting in an earnings surprise of 34.88% [1] - The company posted revenues of $3.7 million for the quarter ended December 2024, missing the Zacks Consensus Estimate by 5.18%, but showing an increase from year-ago revenues of $3.25 million [2] - Over the last four quarters, Vivos Therapeutics has surpassed consensus EPS estimates two times, but has not been able to beat consensus revenue estimates during the same period [2] Stock Performance - Vivos Therapeutics shares have declined approximately 27.5% since the beginning of the year, compared to a decline of 5.1% for the S&P 500 [3] - The current consensus EPS estimate for the upcoming quarter is -$0.41 on revenues of $4.1 million, and for the current fiscal year, it is -$1.43 on revenues of $18.3 million [7] Industry Outlook - The Medical - Drugs industry, to which Vivos Therapeutics belongs, is currently ranked in the top 31% of over 250 Zacks industries, indicating a favorable outlook compared to the bottom 50% [8] - Empirical research suggests a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact Vivos Therapeutics' stock performance [5]